Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
SOUTH SAN FRANCISCO, Calif., March 20, 2017 -- Calithera Biosciences, Inc. (NASDAQ:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced that it intends to offer and sell, subject to market and other conditions, 4,500,000 shares of its common stock in an underwritten public offering. All of the shares of common stock are being offered by Calithera. In connection with this offering, Calithera expects to grant the underwriters a 30-day option to purchase up to 675,000 additional shares of common stock.
Leerink Partners is acting as sole book-running manager for the offering. Wells Fargo Securities is acting as a lead manager and JMP Securities is acting as a co-manager for the offering. The Offering is subject to market conditions, as well as NASDAQ approval, and there can be no assurance as to whether or when the Offering may be completed, or the actual size or terms of the Offering.
A shelf registration statement relating to the offered shares of common stock was filed with the Securities and Exchange Commission (SEC), and was declared effective on November 24, 2015. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website, located at www.sec.gov. Copies of the prospectus related to the offering may be obtained, when available, from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, by email at [email protected], or by telephone at (800) 808-7525, ext. 6132.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Calithera
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera is headquartered in South San Francisco, California.
Investor Relations Contact: Jennifer McNealey [email protected] 650-870-1071
